Literature DB >> 32589334

Zanubrutinib Shows Clinical Benefits in Waldenström Macroglobulinemia.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32589334      PMCID： PMC7330922          DOI： 10.1634/theoncologist.2020-0557

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  3 in total

1.  Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.

Authors:  Constantine S Tam; Judith Trotman; Stephen Opat; Jan A Burger; Gavin Cull; David Gottlieb; Rosemary Harrup; Patrick B Johnston; Paula Marlton; Javier Munoz; John F Seymour; David Simpson; Alessandra Tedeschi; Rebecca Elstrom; Yiling Yu; Zhiyu Tang; Lynn Han; Jane Huang; William Novotny; Lai Wang; Andrew W Roberts
Journal:  Blood       Date:  2019-07-24       Impact factor: 22.113

2.  Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Authors:  Yunhang Guo; Ye Liu; Nan Hu; Desheng Yu; Changyou Zhou; Gongyin Shi; Bo Zhang; Min Wei; Junhua Liu; Lusong Luo; Zhiyu Tang; Huipeng Song; Yin Guo; Xuesong Liu; Dan Su; Shuo Zhang; Xiaomin Song; Xing Zhou; Yuan Hong; Shuaishuai Chen; Zhenzhen Cheng; Steve Young; Qiang Wei; Haisheng Wang; Qiuwen Wang; Lei Lv; Fan Wang; Haipeng Xu; Hanzi Sun; Haimei Xing; Na Li; Wei Zhang; Zhongbo Wang; Guodong Liu; Zhijian Sun; Dongping Zhou; Wei Li; Libin Liu; Lai Wang; Zhiwei Wang
Journal:  J Med Chem       Date:  2019-08-19       Impact factor: 7.446

Review 3.  Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

Authors:  Steven P Treon; Lian Xu; Maria Luisa Guerrera; Cristina Jimenez; Zachary R Hunter; Xia Liu; Maria Demos; Joshua Gustine; Gloria Chan; Manit Munshi; Nicholas Tsakmaklis; Jiaji G Chen; Amanda Kofides; Romanos Sklavenitis-Pistofidis; Mark Bustoros; Andrew Keezer; Kirsten Meid; Christopher J Patterson; Antonio Sacco; Aldo Roccaro; Andrew R Branagan; Guang Yang; Irene M Ghobrial; Jorge J Castillo
Journal:  J Clin Oncol       Date:  2020-02-21       Impact factor: 44.544
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.